Gary S. Jacob, Ph.D. has served as Chairman and Director of ContraVir since May 2013. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Trovagene, Inc., a public diagnostics company and a director and Chief Executive Officer of Synergy Pharmaceuticals Inc. since July 2008. Dr. Jacob also served as Chief Scientific Officer of Synergy from 1999 to 2003 and has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he served as Director of Glycobiology and Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. From 1986 to 1990, Dr. Jacob managed the G.D. Searle Glycobiology Group located at Oxford University, England.
Dr. Jacob earned a B.S. in Chemistry from the University of Missouri, and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.